TFFP — TFF Pharmaceuticals Share Price
- $5.14m
- $1.93m
- $0.73m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.02 | ||
Price to Tang. Book | 1.02 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 6.09 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -387.57% | ||
Return on Equity | -182.42% | ||
Operating Margin | -2325.72% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | n/a | 0.09 | 0.5 | 0.73 | 0.43 | 0.3 | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicine into potent dry powder. It is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- January 24th, 2018
- Public Since
- October 25th, 2019
- No. of Shareholders
- 6
- No. of Employees
- 19
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market
- Shares in Issue
- 3,098,134
![Blurred out image of a map](https://www.stockopedia.com/assets/conversion/images/maps_placeholder.jpg)
- Address
- 2600 Via Fortuna Ste 360, AUSTIN, 78746-7983
- Web
- https://tffpharma.com/
- Phone
- Auditors
- Marcum LLP
Upcoming Events for TFFP
Q3 2024 TFF Pharmaceuticals Inc Earnings Release
Similar to TFFP
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 23:41 UTC, shares in TFF Pharmaceuticals are trading at $1.74. This share price information is delayed by 15 minutes.
Shares in TFF Pharmaceuticals last closed at $1.74 and the price had moved by -85.8% over the past 365 days. In terms of relative price strength the TFF Pharmaceuticals share price has underperformed the S&P500 Index by -88.7% over the past year.
The overall consensus recommendation for TFF Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
TFF Pharmaceuticals does not currently pay a dividend.
TFF Pharmaceuticals does not currently pay a dividend.
TFF Pharmaceuticals does not currently pay a dividend.
To buy shares in TFF Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.74, shares in TFF Pharmaceuticals had a market capitalisation of $5.39m.
Here are the trading details for TFF Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: TFFP
Based on an overall assessment of its quality, value and momentum TFF Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in TFF Pharmaceuticals is $17.00. That is 877.01% above the last closing price of $1.74.
Analysts covering TFF Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$4.70 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TFF Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -79.37%.
As of the last closing price of $1.74, shares in TFF Pharmaceuticals were trading -71.09% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The TFF Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.74.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on TFF Pharmaceuticals' directors